ASX Announcement

20 November 2026

ASX Limited

Market Announcements Office

39 Martin Place

SYDNEY NSW 2000

Re: Healius Limited ('HLS'): Late lodgement of Appendix 3Y – Bruce Robinson

Healius Limited (ASX: HLS) (Company) attaches an Appendix 3Y, Change of Director's Interest Notice, in respect of Bruce Robinson.

The Appendix 3Y was not lodged within the five-business-day timeframe required under ASX Listing Rule 3.19A.2. Following consultation with ASX, ASX has directed the Company under Listing Rule 18.8 to provide the following information.

1. Reason for late lodgement

The Appendix 3Y was lodged late because, as the result of an administrative oversight on the part of the Director, the Company was not notified of the relevant transaction within the required timeframe. The Company became aware of the transaction on 20 November 2026 and lodged the Appendix 3Y promptly after becoming aware of it.

2. Arrangements under Listing Rule 3.19B

The Company has arrangements in place with its Directors to enable it to comply with its disclosure obligations under Listing Rule 3.19A. These include:

- a Board-approved Policy on Trading in Healius Securities, which is publicly available on the Company's website, and which applies specific requirements and restrictions to Directors and Key Management Personnel,
- procedures requiring Directors to promptly notify the Company Secretary of any acquisition, disposal, transfer or other change in their notifiable interests and provide the information required to enable the Company to prepare and lodge the relevant Appendix 3Y, with the declaration of Directors' interests also being a standing agenda item at each Board meeting, and
- periodic guidance provided to Directors regarding their disclosure obligations, including the requirement for the Company to lodge an Appendix 3Y within five business days of a change in a Director's notifiable interests.

3. Additional steps

The Company considers that its existing arrangements are appropriate. However, following this incident, the Company will provide refresher training to all Directors regarding their notification obligations and the Company's securities trading arrangements, and reinforce the importance of promptly providing the Company Secretary with all information necessary to enable the Company to meet its disclosure obligations under the ASX Listing Rules.

This announcement has been authorised for release by the Managing Director and CEO.

For further information please contact:

Investor Enquiries

Andrew Thomson
Chief Financial Officer
Healius Limited
investor.relations@healius.com.au

Media Enquiries

Susannah Rands
Head of Communications
Healius Limited
media@healius.com.au

About Healius Limited

For over 30 years Healius has been one of Australia's leading healthcare companies, committed to supporting quality, affordable and accessible healthcare for all Australians. Through its unique footprint of centres and its 8,500+ employees, Healius provides Australia-wide specialty pathology services to consumers and their referring practitioners.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	HEALIUS LIMITED
ABN	24 064 530 516

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Bruce Robinson
Date of last notice	2 February 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Bruce Gregory Robinson & Alice Ruth Killen Superannuation Fund. Bruce Robinson is a member and beneficiary of the fund.
Date of change	28 October 2026
No. of securities held prior to change	Nil
Class	Fully paid ordinary shares
Number acquired	109,890
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Average price of $0.460 per share

+ See chapter 19 for defined terms.

No. of securities held after change	109,890 fully paid ordinary shares (Indirect)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On market trade

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	-
If prior written clearance was provided, on what date was this provided?	-

Authorised by: Kylie Brown, Company Secretary
Date: 20 November 2026

+ See chapter 19 for defined terms.